Alvotech Ordinary Shares ALVO · Stock Open Alvotech Ordinary Shares in new tab
Alvotech Ordinary Shares Analysis (ALVO)
Is Alvotech Ordinary Shares a good investment? Alvotech Ordinary Shares (ALVO) is currently trading at 5.62 USD. Market analysts have a consensus price target of 6.80 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 32.45. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Alvotech Ordinary Shares is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is 0.23.
Investor FAQ
Does Alvotech Ordinary Shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is Alvotech Ordinary Shares?
Alvotech Ordinary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -0.62.
Company Profile
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Community Discussion